DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Cardiology Homepage

NIH grants over $1 million to development of non-contrast imaging approaches Will be used to diagnose peripheral arterial disease

Elsevier touts new study validating use of STATdx solution Reduced diagnostic errors by as much as 37 percent

Pre-activating cardiac catherization labs benefits EMS STEMI patients on arrival Saves critical minutes and can bypass typical ED protocols

Apple Watch can monitor heart rhythms with FDA approval Detects atrial fibrillation and can tell if you've taken a sudden fall

Keith D. Dawkins InnovHeart elects chairman of the board

Jeffrey S. Brown Endologix appoints chief operations officer

Bioengineers create virtual 3D heart with AI Could provide a boost to the treatment of atrial fibrillation

Fractional flow reserve CT can reduce invasive heart procedures: study First clinical study on benefits of FFRCT for moderate stenosis

Philips unveils new ultrasounds for general and interventional cardiology Equipped with anatomical intelligence

MaxQ-AI seeks $8 million public IPO listing on Nasdaq Will help FDA regulatory processes for Accipio software products

Timothy J. Arens

Surmodics announces leadership change and appointment of interim CFO
May 22, 2018
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as interim CFO. LaFrence has agreed to assist in the orderly transition of his CFO responsibilities. His departure is not related to any disagreement with the company’s accounting principles or practices or financial statement disclosures.

“We greatly appreciate the contributions Andy has made during his tenure at Surmodics and wish him the best in his future endeavors,” said Gary Maharaj, President and Chief Executive Officer of Surmodics. “We are pleased to have a strong and deep finance team at Surmodics, including a smooth transition plan with Tim stepping up in the capacity of interim CFO. Tim's experience in various leadership roles at Surmodics, including previous interim CFO, will provide strong leadership for the team as we continue focusing on growth and ongoing improvements in financial and operational performance."

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“It has been a privilege to work with such an incredible team at Surmodics,” said LaFrence. “I am leaving for a new endeavor that fulfills a personal life-mission.”

Arens has served in his current role since February 2013. He joined Surmodics in February 2007 as Director, Business Development, was named Senior Director and General Manager of the in vitro diagnostics business unit in October 2010 and promoted to Vice President of Finance and interim CFO in August 2011.


About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.

Back to HCB News
  Pages: 1

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED